[Modern neuroprotection in the treatment of patients with cerebrovascular diseases]

Currently, both in Russia and in the world as a whole, the problem of acute and chronic cerebrovascular pathology does not lose its relevance, despite the organizational measures taken to prevent and treat this pathology. The search for highly effective methods of treating stroke patients continues, while preference is given to drugs with polymodal neuroprotective, neuroreparative effects. In this regard, the promising Russian drug cellex, obtained from the embryonic brain tissue of pigs, is of interest. The drug contains tissue-specific signaling proteins and polypeptides (growth factors, differentiation of nerve cells). The article presents the results of a number of experimental and clinical studies proving its primary and secondary neuroprotective effects. In multicenter Russian studies, including placebo-controlled studies, convincing data were obtained on the effectiveness and safety of the drug in the acute and recovery periods of ischemic and hemorrhagic stroke, as well as in chronic brain ischemia. Based on the analysis of the results obtained during the research, it is concluded that it is advisable to use drugs with a pleiotropic effect. The complex of measures that contribute to improving the effectiveness of rehabilitation measures both in the acute and in the recovery period of stroke, as well as in chronic cerebrovascular pathology, should include drugs that have neurotrophic and neuroprotective properties. They significantly contribute to the activation of neuroplasticity capabilities, thereby providing a powerful therapeutic effect. One of the drugs in this group is cellex, which has a decent evidence base of effectiveness and safety.